Monitoring Natural Killer Cells in Multiple Sclerosis Patients Treated With Fingolimod: a Monocentric, Prospective, One Year, Baseline-to-treatment, Open-label Single Group Pilot Trial
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Pharmacodynamics
- 21 Dec 2017 Planned End Date changed from 1 Nov 2017 to 1 Jun 2018.
- 21 Dec 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Jun 2018.
- 21 Dec 2017 Status changed from recruiting to active, no longer recruiting.